Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04969978

Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation

This phase IV clinical trial determines the impact of implementing a Quitline electronic (e)Referral system with an enhanced academic detailing implementation strategy on Quitline reach, tobacco cessation assistance and self-reported quit rates among patients in community health centers. It also examines the cost-effectiveness of Quitline eReferrals both with and without enhanced academic detailing. If this implementation strategy is effective, this strategy could be used to increase tobacco cessation treatment through the collaboration between state Quitlines and community health centers that serve large numbers of socioeconomically disadvantaged patients who use tobacco.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Tobacco-Related Carcinoma Behavior Health Behavior Smoking Smoking &Amp; Tobacco Cessation Tobacco Use Cessation

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

OHSU Knight Cancer Institute

Portland, Oregon, 97239, United States

About this study

PRIMARY OBJECTIVES:

I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers [CHCs]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for tobacco cessation medication, and receipt of in-clinic counseling among patients identified as currently using tobacco.

II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported tobacco quit rates among all patients identified as current persons using tobacco using electronic health record (EHR) data.

III. Estimate the total annual costs and incremental cost-effectiveness of a Quitline eReferral system, with and without enhanced AD.

OUTLINE: Clinics are randomized to 1 of 2 arms.

ARM I: Clinics are notified via email that the eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding electronic health record (EHR) screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.

ARM II: Clinics receive standard online materials and access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the Quitline eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Study Clinic Inclusion Criteria:

  • In Oregon
  • On the OCHIN Epic EHR for >= 1 year
  • Willing to be randomized to the intervention or comparison condition
  • Willing to recruit a provider to serve as a clinic champion (to share monthly performance audit and feedback at all-staff meetings, determine desired content of booster sessions with clinic team members, and complete a survey at the completion of the intervention period) and a clinic manager to coordinate training and booster sessions

Study Patient Inclusion Criteria:

  • Adult patients (>= 18 years of age)
  • Identified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 24-month study period

Treatment and study plan

Enhanced Academic Detailing

Behavioral
  • Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation
  • Follow-up booster sessions
  • Monthly performance audit and feedback

Other names: EAD

Informational intervention

Other

Receive overview of Quitline services and use of Quitline eReferral via online materials

Primary outcomes

  1. Accepted electronic (e)Referral to Quitline

    Time frame: At any point during the 24-month intervention period

    Proportion of patients who accepted a Quitline eReferral in intervention (EAD) versus comparator clinics. Will use a logistic mixed effects model that addresses the following design features of the study: 1) will include random intercept for clinic to account for clustering of patients within clinics; 2) will perform an intent-to-treat analysis; 3) hypothesis tests will be two-sided.

Secondary outcomes

  1. Quitline eReferral offered

    Time frame: At any point during the 24-month intervention period

    Proportion of patients who were offered the Quitline eReferral in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.

  2. Quitline enrollment

    Time frame: At any point during the 24-month intervention period

    Proportion of patients who accepted the Quitline eReferral and enrolled in Quitline services in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.

  3. Receipt of in-office counseling

    Time frame: At any point during the 24-month intervention period

    Proportion of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.

  4. Tobacco cessation medication ordered

    Time frame: At any point during the 24-month intervention period

    Proportion of patients with a tobacco cessation medication in the 'medication orders' list of the EHR in intervention (EAD) versus comparator clinics. Will construct similar logistic mixed effects models.

  5. Tobacco cessation

    Time frame: At any point during the 24-month intervention period or up to 6 months post-intervention

    Proportion of patients with EHR status change from current to former tobacco use. Will utilize similar generalized linear mixed model (GLMM) modeling to estimate the impact of the intervention on cessation outcomes.

  6. Annual intervention costs

    Time frame: Years 1-4

    Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.

  7. Cost-effectiveness

    Time frame: Years 1-4

    Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.

  8. Incremental cost-effectiveness ratio

    Time frame: Years 1-4

    Difference in total costs by study arm, overall and for patients enrolled in Quitline.

Other outcomes

  1. Tobacco use assessed

    Time frame: At any point during the 24-month intervention period

    Proportion of patients who had a current tobacco use assessment in intervention (EAD) versus comparator clinics.

Sponsors and collaborators

Lead sponsor

OHSU Knight Cancer Institute

Other

Collaborators

  • Kaiser Permanente
  • National Cancer Institute (NCI)
  • OCHIN, Inc.
  • Oregon Health and Science University

Registry information

Official study title

CONNECT: COmpreheNsive TraiNing and Engagement in Cessation Treatment

Acronym: CONNECT

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Jul 21, 2021
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.